C4 Therapeutics (CCCC) Change in Accured Expenses (2019 - 2026)

C4 Therapeutics' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$3.5 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 47.67% year-over-year to -$3.5 million; the TTM figure through Mar 2026 stood at -$2.8 million (down 750.6% YoY), while the FY2025 annual figure was -$6.0 million, down 377.43% from the prior year.
• Change in Accured Expenses was -$3.5 million for Q1 2026 at C4 Therapeutics, down from $2.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.2 million in Q4 2023 to a low of -$7.7 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged -$261117.6 across 5 years, with a median of $537000.0 in 2023.
• Biggest YoY gain for Change in Accured Expenses was 669.17% in 2024; the steepest drop was 426.07% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $2.7 million in 2022, then surged by 92.5% to $5.2 million in 2023, then fell by 23.29% to $4.0 million in 2024, then sank by 47.95% to $2.1 million in 2025, then tumbled by 270.23% to -$3.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.5 million (Q1 2026), $2.1 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.